首页|复方苦参注射液在胃癌恶性腹水患者顺铂腹腔灌注化疗中的应用及对免疫功能的影响

复方苦参注射液在胃癌恶性腹水患者顺铂腹腔灌注化疗中的应用及对免疫功能的影响

扫码查看
目的 探讨复方苦参注射液在胃癌恶性腹水患者顺铂腹腔灌注化疗中的应用及对免疫功能的影响.方法 选择2014年4月~2016年2月慈溪市慈林医院收治的胃癌恶性腹水患者90例进行回顾性分析,采用系统随机的方法分为对照组和观察组各45例,对照组单独采用顺铂腹腔灌注化疗进行治疗,观察组采用复方苦参注射液联合者顺铂腹腔灌注化疗进行治疗.对2组患者治疗前及治疗后免疫功能指标水平进行比较,同时观察2组患者治疗后的近期疗效、生活质量的改善情况及不良反应发生情况.结果观察组患者的有效率及控制率均高于对照组患者,但组间差异不明显.观察组患者的稳定率为55.55%明显高于对照组患者的22.22%,组间差异明显(P<0.05).治疗前,2组患者的CD3+、CD4+、CD8+、CD4+/CD8+T细胞亚群及NK细胞比较无显著性差异.治疗后,2组患者的CD3+、CD4+、CD4+/CD8+T细胞亚群及NK细胞较治疗前显著升高(P<0.05),CD8+较治疗前显著降低(P<0.05),而观察组的CD3+、CD4+、CD4+/CD8+T细胞亚群及NK细胞显著高于对照组(P<0.05),CD8+显著低于对照组(P<0.05).对照组患者的生活质量的改善有效率为35.55%与观察组患者的80.00%相比,明显较低,组间比较存在明显差异(P<0.05).观察组患者消化道反应及肝功能异常情况的发生率分别为0.00%、8.88%明显低于对照组患者的11.11%、22.22%,组间存在明显差异(P<0.05).2组患者乏力、恶心、呕吐情况的发生率相比无明显差异.结论 采用复方苦参注射液联合者顺铂腹腔灌注化疗对胃癌恶性腹水患者进行治疗,疗效显著,可以有效改善患者的T细胞亚群及NK细胞,提高患者的免疫功能.
Effect of compound sophora flavescens injection on intraperitoneal chemotherapy of cisplatin in malignant ascites of gastric cancer patients and its influence on immune function
Objective To explore the effect of compound sophora flavescens injection on intraperitoneal chemotherapy of cisplatin in malignant ascites of gastric cancer patients and its influence on immune function.Methods 90 cases with malignant ascites of gastric cancer failures were researched,who from May 2014 to May 2016.According to random number table, they were divided into observation group and control group, 45 cases in each group.The control group was treated with intraperitoneal chemotherapy of cisplatin alone, and the treatment group was treated by intraperitoneal chemotherapy with compound Kushen injection combined with cisplatin.The two groups of patients before and after treatment, compared the level of immune function indicators, while observing the two groups of patients after treatment, short-term efficacy, quality of life improvement and adverse reactions.Results Observation group of patients with efficient and control rates were higher than the control group patients, but no obvious difference between groups.The stability factor of 55.55%of patients with observation group was obviously higher than that of control group 22.22%of the patients, the clear difference between groups (P<0.05).Before the treatment, two groups of patients of CD3 +, CD4 +, CD8 +and CD4 +/CD8 +T cell subsets and NK cells was no significant difference.After treatment, two groups of patients of CD3 +, CD4 +, CD4 +/CD8 + T cell subsets and NK cells were significantly increased than before treatment ( P<0.05 ) , and CD8 + than before treatment significantly reduced ( P <0.05 ) , while the observation group of CD3 +, CD4 +, CD4 +/CD8 +T cell subsets and NK cells was significantly higher than that of control group ( P <0.05 ) , and CD8 + was significantly lower than control group (P <0.05).The control group in the improvement of quality of life of patients with effective rate of 35.55%compared with 80.00% of the observation group of patients, significantly lower, more obvious differences between groups (P <0.05).Observation group of patients the incidence of gastrointestinal reaction and liver function abnormalities were 0.00%, 8.88%, significantly lower than the control group patients were 11.11%, 22.22%, there exists significant difference between groups (P <0.05).Fatigue, nausea, vomiting and 2 groups of patients compared the incidence rate of no significant difference.Conclusion The combined use of compound Kushen injection combined with cisplatin intraperitoneal perfusion chemotherapy in patients with malignant ascites of gastric cancer for treatment,effect is remarkable,Can effectively improve the patient's T cell subsets and NK cells,Improve the patient's immune function.

compound kushen injectionmalignant ascites of gastric cancercisplatinperitoneal perfusionimmune function

马其辉、方黎明、陈日

展开 >

慈溪市慈林医院 消化内科,浙江 慈溪 315315

复方苦参注射液 胃癌恶性腹水 顺铂 腹腔灌注 免疫功能

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.37(2)
  • 8
  • 10